Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced its participation in the 2024 Guggenheim Global Healthcare Conference. President and CEO Zachary Hornby will participate in a fireside chat on Tuesday, November 12, 2024, at 2:30 p.m. ET in Boston, MA. The session will be available via live and archived webcast in the Investors section of the company's website under 'Events & Presentations'.
Boundless Bio (Nasdaq: BOLD), una compagnia oncologica in fase clinica focalizzata sulla biologia del DNA extracromosomico (ecDNA) per trattare i tumori amplificati da oncogeni, ha annunciato la sua partecipazione al 2024 Guggenheim Global Healthcare Conference. Il Presidente e CEO Zachary Hornby parteciperà a una chiacchierata informale martedì 12 novembre 2024, alle 14:30 ET a Boston, MA. La sessione sarà disponibile tramite webcast dal vivo e registrato nella sezione Investitori del sito web dell'azienda sotto 'Eventi e Presentazioni'.
Boundless Bio (Nasdaq: BOLD), una compañía de oncología en etapa clínica enfocada en la biología del ADN extracromosómico (ecDNA) para tratar cánceres amplificados por oncogenes, anunció su participación en la 2024 Guggenheim Global Healthcare Conference. El Presidente y CEO Zachary Hornby participará en una charla informal el martes 12 de noviembre de 2024, a las 2:30 p.m. ET en Boston, MA. La sesión estará disponible a través de una transmisión en vivo y grabada en la sección de Inversionistas del sitio web de la compañía bajo 'Eventos y Presentaciones'.
Boundless Bio (Nasdaq: BOLD)는 종양 유전자 증폭 암을 치료하기 위해 엑스트라 크로모좀 DNA (ecDNA) 생물학에 중점을 둔 임상 단계의 종양학 회사로, 2024 구겐하임 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 사장 겸 CEO인 Zachary Hornby는 2024년 11월 12일 화요일, 오후 2시 30분 ET에 매사추세츠주 보스턴에서 진행되는 파이어사이드 채팅에 참석할 예정입니다. 세션은 회사 웹사이트의 투자자 섹션에서 '이벤트 및 발표' 아래 생중계 및 아카이브 웹 캐스트로 제공될 것입니다.
Boundless Bio (Nasdaq: BOLD), une entreprise de biotechnologie en phase clinique spécialisée dans la biologie de l'ADN extracromosomique (ecDNA) pour traiter les cancers amplifiés par des oncogènes, a annoncé sa participation à la 2024 Guggenheim Global Healthcare Conference. Le président et CEO Zachary Hornby participera à une discussion informelle le mardi 12 novembre 2024 à 14h30 ET à Boston, MA. La session sera disponible en diffusion live et archive dans la section Investisseurs du site web de l'entreprise sous 'Événements et Présentations'.
Boundless Bio (Nasdaq: BOLD), ein klinisches Onkologieunternehmen, das sich auf die Biologie der extrachromosomalen DNA (ecDNA) zur Behandlung von durch Onkogene amplifizierten Krebserkrankungen konzentriert, gab seine Teilnahme an der 2024 Guggenheim Global Healthcare Conference bekannt. President und CEO Zachary Hornby wird am Dienstag, den 12. November 2024, um 14:30 Uhr ET in Boston, MA, an einem informellen Gespräch teilnehmen. Die Sitzung wird live und als aufgezeichnete Übertragung im Investorenbereich der Unternehmenswebsite unter 'Veranstaltungen & Präsentationen' verfügbar sein.
- None.
- None.
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in the 2024 Guggenheim Global Healthcare Conference.
A fireside chat session is scheduled for Tuesday, November 12, 2024, in Boston, MA, at 2:30 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than
For more information, visit www.boundlessbio.com.
Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com
Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com
FAQ
When is Boundless Bio (BOLD) presenting at the 2024 Guggenheim Healthcare Conference?
How can I watch Boundless Bio's (BOLD) Guggenheim Conference presentation?
What type of cancer research does Boundless Bio (BOLD) focus on?
Who will represent Boundless Bio (BOLD) at the 2024 Guggenheim Conference?
